儿童结核病诊断的宿主血液生物标志物:系统综述与荟萃分析
干扰素-γ诱导蛋白10的汇总灵敏度85.2%、特异度59.3%,未达WHO目标。
要点
- 多数达标标志物仅来自单中心报告,需更大队列验证
- 干扰素-γ诱导蛋白10汇总灵敏度85.2%、特异度59.3%,未达WHO目标
核心结论
- 识别出达到WHO儿童结核病诊断目标的宿主血液生物标志物,但多数仅来自单中心报告。
- 荟萃分析不支持干扰素-γ诱导蛋白10作为准确的独立生物标志物。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase、Cochrane CENTRAL、SCOPUS、ClinicalTrials.gov和WHO Global Index Medicus。
- 纳入报告生物标志物浓度和/或诊断准确性的原创研究,对象为15岁以下接受结核病评估的儿童。
- 采用分层双变量模型进行荟萃分析,偏倚风险评估使用QUADAS-2。
主要发现
- 报告的生物标志物类别包括细胞因子/蛋白(39项研究)、mRNA(10项研究)、microRNA(4项研究)和其他(11项研究)。
- 对7项研究的细胞因子干扰素-γ诱导蛋白10进行荟萃分析,汇总灵敏度85.2%(95% CI 71.1-93.1%),特异度59.3%(95% CI 44.7-72.5%),未达WHO目标产品概况。
关键数值与推荐
- WHO结核病诊断目标产品概况:灵敏度≥95%,特异度>98%。
- 参考标准为分枝杆菌培养、核酸扩增检测和/或临床诊断。
- 纳入标准为15岁以下接受结核病评估的儿童,检测抗结核治疗前采集的宿主血液生物标志物。
临床怎么用
- 部分宿主血液生物标志物达到WHO儿童结核病诊断目标,但需在更大队列中验证后方可用于临床决策。
- 干扰素-γ诱导蛋白10不推荐作为独立的儿童结核病诊断标志物。
- 未来应聚焦开发适合低资源环境的即时检测方法。
局限性
- 多数达到WHO目标的生物标志物仅来自单中心报告。
- 需要高质量研究在更大队列中验证宿主血液生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current tuberculosis (TB) diagnostics have limited sensitivity in children, resulting in undiagnosed and untreated cases; host blood biomarkers have the potential to narrow this diagnostic gap. OBJECTIVES: To conduct a systematic review to identify host blood biomarkers that diagnose childhood TB and to summarize biomarker accuracy. METHODS: DATA SOURCES: MEDLINE, Embase, Cochrane Central Register of Controlled Trials, SCOPUS, ClinicalTrials.gov, and WHO Global Index Medicus. STUDY ELIGIBILITY CRITERIA: Original studies that reported biomarker concentration and/or diagnostic accuracy for childhood TB. PARTICIPANTS: Children <15 years undergoing evaluation for TB disease. TESTS: Any host blood biomarker measured before anti-TB therapy. REFERENCE STANDARD: Mycobacterial culture, nucleic acid amplification tests, and/or clinical diagnosis. ASSESSMENT OF RISK OF BIAS: Quality Assessment of Diagnostic Accuracy Studies-2. METHODS OF DATA SYNTHESIS: A hierarchical bivariate model was used for meta-analysis. RESULTS: Fifty-five studies were included, of which 42 (76.4%) studies were at high risk of bias and/or had applicability concerns. The following biomarker classes were reported: cytokine/protein (n = 39 studies), mRNA (n = 10 studies), microRNA (n = 4 studies), and other (n = 11 studies). Twelve biosignatures (seven cytokine, four metalloproteinase, one microRNA) and two individual biomarkers (one cytokine, one metalloproteinase) met the WHO target product profile for TB disease diagnosis (sensitivity ≥95%, specificity >98%). Meta-analysis was conducted for the cytokine interferon-γ-inducible protein 10 from seven studies; summary estimates of sensitivity (85.2%, 95% CI, 71.1-93.1%) and specificity (59.3%, 95% CI, 44.7-72.5%) did not meet WHO target product profile. DISCUSSION: Host blood biomarkers were identified that met WHO targets for childhood TB disease diagnosis; however, most were reported from a single centre. Meta-analysis did not support interferon-γ-inducible protein 10 as an accurate stand-alone biomarker. High-quality studies are needed to validate host blood biomarkers in larger cohorts, and future work should focus on the development of point-of-care tests suitable for low-resource settings.
引用
- Prodanuk M, King JW, Cunningham J, et al. Host blood biomarkers for the diagnosis of childhood tuberculosis disease: a systematic review and meta-analysis. Clin Microbiol Infect. 2026. PMID: 41796962. doi:10.1016/j.cmi.2026.02.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。